Are Aarti Pharma latest results good or bad?
Aarti Pharma's latest results are concerning, with net sales declining to Rs 386.19 crore, the lowest in five quarters, and significant drops in both Profit Before Tax and Profit After Tax. The company is facing operational challenges, reflected in a 31.50% QoQ decline in net sales and a 43.97% QoQ decline in net profit.
Aarti Pharmalabs has reported its financial results for the quarter ending June 2025, which indicate significant challenges in its operational performance. The company's net sales for this quarter were recorded at Rs 386.19 crore, reflecting a notable decline compared to the previous four quarters, marking the lowest sales figure in the last five quarters. Profit Before Tax (PBT) also saw a substantial decline, falling to Rs 63.85 crore, which is a decrease from the average PBT in the preceding quarters. Similarly, Profit After Tax (PAT) dropped to Rs 49.50 crore, indicating a downward trend in profitability. The earnings per share (EPS) reached Rs 5.46, the lowest in five quarters, further highlighting the company's declining financial health.
The debt-equity ratio has increased to 0.21 times, the highest in the last five half-yearly periods, suggesting a rise in borrowing to support operations. Additionally, the quarterly results show a QoQ decline in net sales of 31.50% and a QoQ decline in consolidated net profit of 43.97% compared to the previous quarter.
Overall, Aarti Pharmalabs is facing significant operational challenges, and the company has experienced an adjustment in its evaluation based on these results.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
